Lux Biosciences Eye Drug Set to Receive Orphan Designation

Pharmaceutical Business Review

An EMEA committee has adopted a positive opinion on orphan medicinal product designation for Lux Biosciences' investigational therapeutic for the treatment of chronic, non-infectious uveitis.
  • <<
  • >>

Comments